Hhg Company Lowers stake in Pfizer (PFE)

Pfizer (PFE) : Hhg Company reduced its stake in Pfizer by 1.81% during the most recent quarter end. The investment management company now holds a total of 370,894 shares of Pfizer which is valued at $12,339,643 after selling 6,821 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Apr 20, 2016.Pfizer makes up approximately 3.37% of Hhg Company’s portfolio.

Pfizer opened for trading at $33.25 and hit $33.5 on the upside on Friday, eventually ending the session at $33.27, with a gain of 0.09% or 0.03 points. The heightened volatility saw the trading volume jump to 2,61,37,321 shares. Company has a market cap of $205,746 M.

Other Hedge Funds, Including , Aull Monroe Investment Management Corp reduced its stake in PFE by selling 21 shares or 0.03% in the most recent quarter. The Hedge Fund company now holds 70,992 shares of PFE which is valued at $2,361,904. Pfizer makes up approx 1.39% of Aull Monroe Investment Management Corp’s portfolio.Eastern Bank reduced its stake in PFE by selling 711 shares or 1.09% in the most recent quarter. The Hedge Fund company now holds 64,557 shares of PFE which is valued at $2,098,103. Pfizer makes up approx 0.17% of Eastern Bank’s portfolio.Prospera Financial Services Inc reduced its stake in PFE by selling 131 shares or 0.55% in the most recent quarter. The Hedge Fund company now holds 23,482 shares of PFE which is valued at $763,165. Pfizer makes up approx 0.17% of Prospera Financial Services Inc’s portfolio.Capital Investment Services Of America reduced its stake in PFE by selling 900 shares or 6.88% in the most recent quarter. The Hedge Fund company now holds 12,172 shares of PFE which is valued at $388,165. Pfizer makes up approx 0.07% of Capital Investment Services Of America’s portfolio.

On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.

Many Wall Street Analysts have commented on Pfizer. Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.